ADAPTED

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
ADAPTED logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 5
Grant agreement number
115975

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
3 510 000
EFPIA in kind
3 286 740
Total Cost
6 796 740

Summary

Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well-known risk factor for developing the disease, but precisely how this gene contributes to the risk of developing AD is not known. People who carry the APOE4 version of the gene have a considerably higher risk of developing AD. They also tend to develop the disease much earlier in life. However, the reasons for this are not well understood and therefore APOE has largely been ignored in the quest to find treatments for AD. By bringing together leading experts in a range of state-of-the-art technologies, including three research-intensive small and medium-sized enterprises (SMEs), ADAPTED hopes to gain better insights into the causes of AD, something that will in turn lead to better treatments for patients.

Participants Show participants on map

EFPIA companies
  • Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany
  • Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Agencia Estatal Consejo Superior Deinvestigaciones Cientificas, Madrid, Spain
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Fundacio Ace, Barcelona , Spain
  • Klinikum Der Universitaet Zu Koeln, Cologne, Germany
  • Universitatsklinikum Bonn, Bonn, Germany
  • Universiteit Leiden, Leiden, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Caebi Bioinformatica Sociedad Limitada, Sevilla, Spain
  • Dc Biosceinces LTD, Dundee, United Kingdom
  • Mimetas BV, Leiden, Netherlands
  • Modus Research And Innovation Limited, Dundee, United Kingdom

CONTACT

Project coordinator
Miren GURRUTXAGA
FUNDACIO ACE
miren[at]fundacioace.com
Project leader
Margot H.M. Bakker
AbbVie Deutschland GmbH & Co. K.G.
margot.bakker[at]abbvie.com